标题
Poly (ADP-Ribose) Polymerase Inhibitors: Talazoparib in Ovarian Cancer and Beyond
作者
关键词
-
出版物
Drugs in research & development
Volume 20, Issue 2, Pages 55-73
出版商
Springer Science and Business Media LLC
发表日期
2020-03-26
DOI
10.1007/s40268-020-00301-8
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- SOLO1 versus SOLO2: Cost-effectiveness of olaparib as maintenance therapy for newly diagnosed and platinum-sensitive recurrent ovarian carcinoma among women with germline BRCA mutations (gBRCAmut).
- (2019) Juliet Elizabeth Wolford et al. JOURNAL OF CLINICAL ONCOLOGY
- Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial
- (2019) Kathleen N Moore et al. LANCET ONCOLOGY
- PARP Inhibitors in Ovarian Cancer: The Route to “Ithaca”
- (2019) Boussios et al. Diagnostics
- Combined Strategies with Poly (ADP-Ribose) Polymerase (PARP) Inhibitors for the Treatment of Ovarian Cancer: A Literature Review
- (2019) Stergios Boussios et al. Diagnostics
- Neoadjuvant Talazoparib for Patients With Operable Breast Cancer With a Germline BRCA Pathogenic Variant
- (2019) Jennifer K. Litton et al. JOURNAL OF CLINICAL ONCOLOGY
- Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
- (2019) Antonio González-Martín et al. NEW ENGLAND JOURNAL OF MEDICINE
- Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer
- (2019) Robert L. Coleman et al. NEW ENGLAND JOURNAL OF MEDICINE
- LBA8_PRKEYNOTE-522: Phase III study of pembrolizumab (pembro) + chemotherapy (chemo) vs placebo (pbo) + chemo as neoadjuvant treatment, followed by pembro vs pbo as adjuvant treatment for early triple-negative breast cancer (TNBC)
- (2019) P Schmid et al. ANNALS OF ONCOLOGY
- Veliparib in ovarian cancer: a new synthetically lethal therapeutic approach
- (2019) Stergios Boussios et al. INVESTIGATIONAL NEW DRUGS
- Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer (NSGO-AVANOVA2/ENGOT-ov24): a randomised, phase 2, superiority trial
- (2019) Mansoor Raza Mirza et al. LANCET ONCOLOGY
- RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer
- (2018) C Cruz et al. ANNALS OF ONCOLOGY
- Selective Loss of PARG Restores PARylation and Counteracts PARP Inhibitor-Mediated Synthetic Lethality
- (2018) Ewa Gogola et al. CANCER CELL
- An Effective Epigenetic-PARP Inhibitor Combination Therapy for Breast and Ovarian Cancers Independent of BRCA Mutations
- (2018) Nicholas Pulliam et al. CLINICAL CANCER RESEARCH
- An open-label, phase II basket study of olaparib and durvalumab (MEDIOLA): Results in germline BRCA -mutated ( gBRCA m) platinum-sensitive relapsed (PSR) ovarian cancer (OC)
- (2018) Y. Drew et al. GYNECOLOGIC ONCOLOGY
- Topacio: Preliminary activity and safety in patients (pts) with platinum-resistant ovarian cancer (PROC) in a phase 1/2 study of niraparib in combination with pembrolizumab
- (2018) P.A. Konstantinopoulos et al. GYNECOLOGIC ONCOLOGY
- Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial
- (2018) Noel Clarke et al. LANCET ONCOLOGY
- Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial
- (2018) Sibylle Loibl et al. LANCET ONCOLOGY
- The long tail of oncogenic drivers in prostate cancer
- (2018) Joshua Armenia et al. NATURE GENETICS
- TOPACIO/Keynote-162 (NCT02657889): A phase 1/2 study of niraparib + pembrolizumab in patients (pts) with advanced triple-negative breast cancer or recurrent ovarian cancer (ROC)—Results from ROC cohort.
- (2018) Panagiotis A. Konstantinopoulos et al. JOURNAL OF CLINICAL ONCOLOGY
- Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation
- (2018) Jennifer K. Litton et al. NEW ENGLAND JOURNAL OF MEDICINE
- Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma
- (2018) Olga Kondrashova et al. Nature Communications
- 999TiPOVARIO: A single-arm, open-label phase II study of maintenance therapy with niraparib + bevacizumab (bev) in patients (pts) with advanced ovarian cancer (OC) after response to frontline platinum-based chemotherapy (chemo)
- (2018) M Hardesty et al. ANNALS OF ONCOLOGY
- A Phase II Study of Talazoparib After Platinum or Cytotoxic Nonplatinum Regimens in Patients With Advanced Breast Cancer and Germline BRCA1/2 Mutations (ABRAZO)
- (2018) Nicholas C. Turner et al. CLINICAL CANCER RESEARCH
- Mechanisms of PARP inhibitor resistance in cancer and insights into the DNA damage response
- (2018) Paola Francica et al. Genome Medicine
- Genomic signatures as predictive biomarkers of homologous recombination deficiency in ovarian cancer
- (2017) Adriaan Vanderstichele et al. EUROPEAN JOURNAL OF CANCER
- A Cost-Effectiveness Analysis of Three PARP Inhibitors for Maintenance Therapy in Platinum-Sensitive Recurrent Ovarian Cancer
- (2017) A.Y. Liu et al. GYNECOLOGIC ONCOLOGY
- Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2
- (2017) Amit M. Oza et al. GYNECOLOGIC ONCOLOGY
- Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers
- (2017) Karoline B. Kuchenbaecker et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Gene expression and mutation-guided synthetic lethality eradicates proliferating and quiescent leukemia cells
- (2017) Margaret Nieborowska-Skorska et al. JOURNAL OF CLINICAL INVESTIGATION
- Safety and Clinical Activity of the Programmed Death-Ligand 1 Inhibitor Durvalumab in Combination With Poly (ADP-Ribose) Polymerase Inhibitor Olaparib or Vascular Endothelial Growth Factor Receptor 1-3 Inhibitor Cediranib in Women's Cancers: A Dose-Escalation, Phase I Study
- (2017) Jung-Min Lee et al. JOURNAL OF CLINICAL ONCOLOGY
- Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial
- (2017) Elizabeth M Swisher et al. LANCET ONCOLOGY
- Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial
- (2017) Eric Pujade-Lauraine et al. LANCET ONCOLOGY
- A Small-Molecule Inhibitor of WEE1, AZD1775, Synergizes with Olaparib by Impairing Homologous Recombination and Enhancing DNA Damage and Apoptosis in Acute Leukemia
- (2017) Tamara B. Garcia et al. MOLECULAR CANCER THERAPEUTICS
- Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients
- (2017) Ahmet Zehir et al. NATURE MEDICINE
- HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures
- (2017) Helen Davies et al. NATURE MEDICINE
- Synthetic lethality and cancer
- (2017) Nigel J. O'Neil et al. NATURE REVIEWS GENETICS
- Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
- (2017) Mark Robson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Current status of poly(ADP-ribose) polymerase inhibitors and future directions
- (2017) Akihiro Ohmoto et al. OncoTargets and Therapy
- Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers
- (2017) Johann de Bono et al. Cancer Discovery
- Olaparib monotherapy in patients with advanced relapsed ovarian cancer and a germlineBRCA1/2mutation: a multistudy analysis of response rates and safety
- (2016) U. A. Matulonis et al. ANNALS OF ONCOLOGY
- PARP inhibitors for BRCA1/2-mutated and sporadic ovarian cancer: current practice and future directions
- (2016) G E Konecny et al. BRITISH JOURNAL OF CANCER
- ABCB1 (MDR1) induction defines a common resistance mechanism in paclitaxel- and olaparib-resistant ovarian cancer cells
- (2016) Aparajitha Vaidyanathan et al. BRITISH JOURNAL OF CANCER
- A Radiotracer Strategy to Quantify PARP-1 Expression In Vivo Provides a Biomarker That Can Enable Patient Selection for PARP Inhibitor Therapy
- (2016) M. Makvandi et al. CANCER RESEARCH
- PARP Inhibitor Activity Correlates with SLFN11 Expression and Demonstrates Synergy with Temozolomide in Small Cell Lung Cancer
- (2016) Benjamin H. Lok et al. CLINICAL CANCER RESEARCH
- Update on Poly-ADP-ribose polymerase inhibition for ovarian cancer treatment
- (2016) Anselmo Papa et al. Journal of Translational Medicine
- Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer
- (2016) Colin C. Pritchard et al. NEW ENGLAND JOURNAL OF MEDICINE
- Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action
- (2016) Y. Pommier et al. Science Translational Medicine
- An Adaptive Study to Determine the Optimal Dose of the Tablet Formulation of the PARP Inhibitor Olaparib
- (2016) J. Mateo et al. Targeted Oncology
- CDK12 Inhibition Reverses De Novo and Acquired PARP Inhibitor Resistance in BRCA Wild-Type and Mutated Models of Triple-Negative Breast Cancer
- (2016) Shawn F. Johnson et al. Cell Reports
- The development of PARP inhibitors in ovarian cancer: from bench to bedside
- (2015) Yvette Drew BRITISH JOURNAL OF CANCER
- Olaparib Monotherapy in Patients With Advanced Cancer and a GermlineBRCA1/2Mutation
- (2015) Bella Kaufman et al. JOURNAL OF CLINICAL ONCOLOGY
- Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial
- (2015) Sean Kehoe et al. LANCET
- Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer
- (2015) P. A. Konstantinopoulos et al. Cancer Discovery
- Linking off-target kinase pharmacology to the differential cellular effects observed among PARP inhibitors
- (2015) Albert A. Antolín et al. Oncotarget
- Non-homologous end joining: Emerging themes and unanswered questions
- (2014) Sarvan Kumar Radhakrishnan et al. DNA REPAIR
- Clinical Evaluation of a Multiple-Gene Sequencing Panel for Hereditary Cancer Risk Assessment
- (2014) Allison W. Kurian et al. JOURNAL OF CLINICAL ONCOLOGY
- Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study
- (2014) Joyce F Liu et al. LANCET ONCOLOGY
- Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial
- (2014) Jonathan Ledermann et al. LANCET ONCOLOGY
- Transcriptionally active chromatin recruits homologous recombination at DNA double-strand breaks
- (2014) François Aymard et al. NATURE STRUCTURAL & MOLECULAR BIOLOGY
- PARP-2 and PARP-3 are selectively activated by 5′ phosphorylated DNA breaks through an allosteric regulatory mechanism shared with PARP-1
- (2014) Marie-France Langelier et al. NUCLEIC ACIDS RESEARCH
- Genome-wide Profiling of Genetic Synthetic Lethality Identifies CDK12 as a Novel Determinant of PARP1/2 Inhibitor Sensitivity
- (2013) I. Bajrami et al. CANCER RESEARCH
- BMN 673, a Novel and Highly Potent PARP1/2 Inhibitor for the Treatment of Human Cancers with DNA Repair Deficiency
- (2013) Y. Shen et al. CLINICAL CANCER RESEARCH
- New Strategies in the Treatment of Ovarian Cancer: Current Clinical Perspectives and Future Potential
- (2013) S. Banerjee et al. CLINICAL CANCER RESEARCH
- Stereospecific PARP Trapping by BMN 673 and Comparison with Olaparib and Rucaparib
- (2013) J. Murai et al. MOLECULAR CANCER THERAPEUTICS
- Replication stress links structural and numerical cancer chromosomal instability
- (2013) Rebecca A. Burrell et al. NATURE
- Signatures of mutational processes in human cancer
- (2013) Ludmil B. Alexandrov et al. NATURE
- Predictive biomarkers for cancer therapy with PARP inhibitors
- (2013) J Michels et al. ONCOGENE
- Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors
- (2012) J. Murai et al. CANCER RESEARCH
- Association Between BRCA1 and BRCA2 Mutations and Survival in Women With Invasive Epithelial Ovarian Cancer
- (2012) Kelly L. Bolton JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- BRCA Mutation Frequency and Patterns of Treatment Response in BRCA Mutation–Positive Women With Ovarian Cancer: A Report From the Australian Ovarian Cancer Study Group
- (2012) Kathryn Alsop et al. JOURNAL OF CLINICAL ONCOLOGY
- Identification and evaluation of a potent novel ATR inhibitor, NU6027, in breast and ovarian cancer cell lines
- (2011) A Peasland et al. BRITISH JOURNAL OF CANCER
- Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study
- (2011) Karen A Gelmon et al. LANCET ONCOLOGY
- The underlying mechanism for the PARP and BRCA synthetic lethality: Clearing up the misunderstandings
- (2011) Thomas Helleday Molecular Oncology
- Integrated genomic analyses of ovarian carcinoma
- (2011) D. Bell et al. NATURE
- Nonhomologous end joining drives poly(ADP-ribose) polymerase (PARP) inhibitor lethality in homologous recombination-deficient cells
- (2011) A. G. Patel et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The potential for poly (ADP-ribose) polymerase inhibitors in cancer therapy
- (2011) M. Javle et al. Therapeutic Advances in Medical Oncology
- 53BP1 Inhibits Homologous Recombination in Brca1-Deficient Cells by Blocking Resection of DNA Breaks
- (2010) Samuel F. Bunting et al. CELL
- Perspective on the Pipeline of Drugs Being Developed with Modulation of DNA Damage as a Target
- (2010) R. Plummer CLINICAL CANCER RESEARCH
- Somatic Mutations in BRCA1 and BRCA2 Could Expand the Number of Patients That Benefit From Poly (ADP Ribose) Polymerase Inhibitors in Ovarian Cancer
- (2010) Bryan T.J. Hennessy et al. JOURNAL OF CLINICAL ONCOLOGY
- A Synthetic Lethal Therapeutic Approach: Poly(ADP) Ribose Polymerase Inhibitors for the Treatment of Cancers Deficient in DNA Double-Strand Break Repair
- (2008) Alan Ashworth JOURNAL OF CLINICAL ONCOLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now